Compass Therapeutics (CMPX) said it will review topline secondary endpoints from its Phase 2/3 COMPANION-002 study of Tovecimig plus Paclitaxel in advanced biliary tract cancer. The update is a clinical development milestone, but the article does not include results, magnitude, or guidance changes. Market impact is likely limited until the topline data are disclosed.
Compass Therapeutics (CMPX) said it will review topline secondary endpoints from its Phase 2/3 COMPANION-002 study of Tovecimig plus Paclitaxel in advanced biliary tract cancer. The update is a clinical development milestone, but the article does not include results, magnitude, or guidance changes. Market impact is likely limited until the topline data are disclosed.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
